Bullish Gartley
About CFMS
Conformis, Inc. (NASDAQ: CFMS), is a medical device/ technology company that uses its proprietary iFit 'Image-to-Implant' technology platform to develop, manufacture and sell patient specific joint replacement implants that are designed to fit each patient's unique anatomy.
Technicals
Conclusion:
CFMS has sufficient funds, great management and recently received some 510 certifications while broader markets were selling off. Looking to re-claim those prior gains. Will revisit the trade at or around time of the gap filling.
Like and follow so I can continue finding awesome charts and trades. Thank you in advance d+)
Twitter + Instagram VolatilityWatch
Disclosure: I am long CFMS. This is not a note to buy or sell, please do your homework before investing.
Conformis, Inc. (NASDAQ: CFMS), is a medical device/ technology company that uses its proprietary iFit 'Image-to-Implant' technology platform to develop, manufacture and sell patient specific joint replacement implants that are designed to fit each patient's unique anatomy.
Technicals
- Bullish Gartley pattern (786 retracement)
- Fibonacci confluence at the 1.272 extension
- 382 continuation pattern (Keeps bouncing off and making higher lows-- if it continues it could be used to further add)
- In-line with Fibonacci time-cycles
- RSI pushing higher on Daily and Weekly
- Potential gap up to fill up to the $2.75 level.
Conclusion:
CFMS has sufficient funds, great management and recently received some 510 certifications while broader markets were selling off. Looking to re-claim those prior gains. Will revisit the trade at or around time of the gap filling.
Like and follow so I can continue finding awesome charts and trades. Thank you in advance d+)
Twitter + Instagram VolatilityWatch
Disclosure: I am long CFMS. This is not a note to buy or sell, please do your homework before investing.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.